An experimental drug has blocked the progression of prostate cancer in an animal model with an aggressive form of the disease, new research shows. The agent, OSU-HDAC42, belongs to a new class of drugs called histone deacetylase (HDAC) inhibitors, compounds designed to reactivate genes that normally protect against cancer but are turned off ...

(From ScienceDaily). Given the tools and the knowledge of modern biotechnology, there are a great many potential targeted approaches that can defeat cancer. This one uses an otherwise harmless engineered chemical that becomes toxic in the presence of cancer. Researchers ''had developed a protoxin, named PRX302, by modifying an inactive molecule, ...